BERG, LLC is a clinical-stage, artificial intelligence-powered biotech leveraging its proprietary platform, Interrogative Biology®, to map disease and revolutionize treatments across oncology, neurology and rare diseases. By taking a Back to Biology™ approach, BERG is able to identify critical biomarkers that can accelerate the discovery and development of treatments. BERG has leveraged both Interrogative Biology® and traditional R&D methods to develop a pipeline of first-in-class product candidates and diagnostics that advance bold innovations that have the potential to improve patient lives.